Background: The GABAergic neuroactive steroid (3a,5a)-3-hydroxy-pregnan-20-one (3a,5a-THP; allopregnanolone) enhances GABAergic activity and produces subjective effects similar to ethanol (EtOH). The effect of chronic alcohol exposure on 3a,5a-THP concentrations has been studied in mouse, rat, and monkey limbic brain areas. Chronic EtOH exposure produced divergent brain region and cell-specific changes in 3a,5a-THP concentrations in animal studies. However, 3a,5a-THP levels in similar human brain regions have never been examined in individuals diagnosed with alcohol use disorder (AUD). Therefore, we used immunohistochemistry (IHC) to examine 3a,5a-THP levels in the ventral tegmental area (VTA), substantia nigra pars medialis (SNM), and amygdala of human postmortem brains of patients diagnosed with AUD compared with social drinkers. The effects of sex and liver disease on 3a,5a-THP concentrations were examined in the aforementioned brain regions.
A LCOHOL USE DISORDER (AUD) is a chronic relapsing disorder that is one of the leading causes of lost human potential worldwide. A major goal of basic research on AUD is to understand the transition from alcohol use to alcohol dependence by revealing changes in neurotransmitter systems (Tabakoff and Hoffman, 2013) . The c-aminobutyric acid type A (GABA A ) receptors contribute to the behavioral effects of ethanol (EtOH) and play central roles in the short-and longterm effects of alcohol (Kumar et al., 2009) . The function of GABA A receptors is modulated by potent endogenous neuroactive steroids that are produced in the brain, adrenal glands, and gonads (Gunn et al., 2015) .
The GABAergic neuroactive steroids function as positive allosteric modulators of GABA A receptors, enhancing GABAergic function at nanomolar concentrations (Morrow et al., 1987) . GABAergic neuroactive steroids act through specific binding sites on the a subunits to increase GABA A receptor activity to produce effects pharmacologically similar to EtOH (Hosie et al., 2006) . Systemic administration of GABAergic neuroactive steroids exerts pharmacological responses including anxiolytic, antidepressant, anticonvulsant, sedative, and anesthetic effects in animal models and human studies that reflect their actions on GABA A receptors (Belelli et al., 1989; Bitran et al., 1991; Hogskilde et al., 1987; Khisti et al., 2000) .
The effects of EtOH involve several GABAergic mechanisms that contribute to many of its behavioral actions. (3a,5a)-3-hydroxy-pregnan-20-one (3a,5a-THP or allopregnanolone) is one of the most potent GABAergic steroids and has been frequently studied in alcohol research. EtOH increases de novo synthesis of 3a,5a-THP in rat brain ( VanDoren et al., 2000) , likely contributing to the changes in the GABA A receptor function. Moreover, neuroactive steroids contribute to alcohol sensitivity and may influence the risk of AUD Porcu and Morrow, 2014) . Increasing evidence suggests that 3a,5a-THP, like EtOH, plays a role in modulating plastic changes on GABA A receptors Follesa et al., 2000 Follesa et al., , 2006 . Taken together, brain 3a,5a-THP levels are involved in various mechanisms of alcohol-related effects in central nervous system.
Recent studies elucidated the connection between chronic EtOH exposure and brain 3a,5a-THP levels. Studies in animals have shown that 17 days of voluntary EtOH drinking under limited access conditions produced a 1.65-fold increase in whole brain 3a,5a-THP concentration in male C57BL/6J mice, but not in the female mice (Finn et al., 2004 (Finn et al., , 2010 . High levels of EtOH consumed in liquid diet for 14 days produced a small decrease in cortical 3a,5a-THP levels in male EtOH-dependent rats, but not in the female rats, while cortical 3a,5a-THP levels did not differ in EtOH-withdrawn rats versus controls (Janis et al., 1998) . Similarly, 2-month daily intragastric EtOH administration and withdrawal decreased 3a,5a-THP content measured by gas chromatography-mass spectroscopy in cerebral cortex and hippocampus in Sprague Dawley rats (Cagetti et al., 2004) . Recent studies using immunohistochemistry (IHC) showed that intermittent EtOH exposure and withdrawal over 4 weeks decreases cellular 3a,5a-THP levels in the medial prefrontal cortex, ventral tegmental area (VTA), nucleus accumbens core, lateral amygdala, central nucleus of the amygdala, and dorsolateral striatum in C57BL/6J mice, but increases 3a,5a-THP levels in the CA3 pyramidal cell layer of the hippocampus, and does not alter 3a,5a-THP levels in several other limbic brain regions (Maldonado-Devincci et al., 2014) . In cynomolgus monkeys, 12 months of voluntary EtOH consumption decreases 3a,5a-THP levels in lateral amygdala and basolateral amygdala where 3a,5a-THP immunoreactivity densities were negatively correlated with average daily drinking (Beattie et al., 2015) . These animal studies have shown that EtOH produces divergent brain and cell-specific changes in 3a,5a-THP concentrations, which can differ across species.
The role 3a,5a-THP in alcohol actions in humans have been examined in only a few studies, primarily sampling human blood. Human male and female adolescents seen in the emergency room for alcohol intoxication had elevated 3a,5a-THP plasma levels Ortega, 2003, 2004) . In contrast, ingestion of 3 standard drinks over 1 hour failed to alter plasma 3a,5a-THP or other GABAergic neurosteroid levels in laboratory settings (Holdstock et al., 2006; PierucciLagha et al., 2006; Porcu et al., 2010) , suggesting that alcohol dose might be a key factor. In addition, pretreatment with the neurosteroidogenic enzyme inhibitors finasteride and dutasteride reduced the subjective effects of acute alcohol administration in humans (Covault et al., 2014; PierucciLagha et al., 2005) . Studies on human AUD patients have shown that plasma 3a,5a-THP levels are decreased in early alcohol withdrawal and returned to normal levels upon recovery (Romeo et al., 1996) . Recently, a study sampling postmortem human tissue has shown that pregnenolone (a precursor to 3a,5a-THP) and dehydroepiandrosterone (DHEA; a precursor of the GABAergic steroid androsterone) levels were higher in several limbic brain areas of AUD patients compared with nonalcoholic controls, although testosterone levels were similar in the same regions across groups (Karkkainen et al., 2016) . To our knowledge, this is the first study of brain 3a,5a-THP levels in human AUD patients.
The VTA is part of the mesolimbic pathway and is strongly implicated in EtOH reinforcement (McBride et al., 1999) . Recently, our laboratory has shown that viral vector-mediated overexpression of the P450scc enzyme, the rate-limiting mitochondrial enzyme initiating steroidogenesis, causes an increase in 3a,5a-THP immunoreactivity in the VTA and reduces operant EtOH self-administration in rats (Cook et al., 2014b) , suggesting that 3a,5a-THP levels in the VTA may regulate EtOH drinking. Furthermore, chronic intermittent EtOH exposure reduced 3a,5a-THP immunoreactivity in VTA of C57BL/6J mice (Maldonado-Devincci et al., 2014) . The substantia nigra is part of the midbrain dopamine system and provides dopaminergic tone necessary for voluntary movement (Bissonette and Roesch, 2016) . Substantia nigra pars medialis (SNM) is located in the ventromedial aspect of the substantia nigra pars compacta (SNC) (Halliday, 2012) , next to the VTA. Recent findings suggest that dopaminergic neurons in the SNC may also play a role in reward prediction processes (Matsumoto and Hikosaka, 2009 ) and EtOH consumption (Kim et al., 2015) . Dopaminergic neurons in the ventromedial region in the SNC and VTA primarily project to the ventral striatum and transfer information related to reward values (Matsumoto and Hikosaka, 2009; Nomoto et al., 2010) . The amygdala is a brain region that affects multiple aspects of human behavior, including anxiety (Gilpin et al., 2015) and alcohol seeking (Chaudhri et al., 2013) . Long-term EtOH exposure has been shown to alter 3a,5a-THP levels in the amygdala subregions studied in mice (Maldonado-Devincci et al., 2014) and monkeys (Beattie et al., 2015) . This study examined the effects of AUD on 3a,5a-THP levels in the VTA, SNM, and amygdala of human postmortem brains.
MATERIALS AND METHODS

Subjects
Formalin-fixed paraffin-embedded (FFPE) human postmortem brain sections from 38 AUD patients and 27 control cases were obtained from the New South Wales Brain Tissue Resource Center (NSWBTRC) at the University of Sydney in Australia. Clinical information regarding subjects was provided by NSWBTRC, including age, sex, cause of death, smoking history, liver pathology, lifetime alcohol consumption (kg), average daily EtOH intake (gram), and total drinking years. American Psychiatric Association (1994) DSM-IV criteria were used to diagnose patients for AUD. Comorbidity with neurologic, psychiatric, and neurodegenerative disorders was the exclusion criterion for this study to eliminate confounding factors. Sex, age, alcohol consumption rate, postmortem interval (PMI), and lengths of the tissue fixation time in AUD patients and control subjects are reported in Table 1 . Cardiovascular and respiratory system-related complications were the most common causes of death for the AUD patients (58%) and control cases (87%).
Pathological information regarding postmortem human samples was provided by NSWBTRC, including brain pH, PMI, and length of tissue fixation time (Table 1 ). The mean brain pH was 6.5 AE 0.1 for all groups. Length of tissue fixation time varied between brain regions that are included in the study. The average fixation time for VTA and SNM regions, which are located in human midbrain, averaged 23.5 AE 1 days. However, human amygdala samples were stored in formalin for 6 AE 1 years.
Effect of the liver status was examined to determine whether liver pathology contributed to the effect of AUD on 3a,5a-THP immunoreactivity. Autopsy information of pathological changes was categorized as normal liver, congestion, mild or moderate steatosis (fatty liver), and cirrhosis. Among AUD patients, 55% of the subjects were complicated with liver cirrhosis, 40% of the subjects had congestion or mild to moderate steatosis, and only 5% of the subjects had normal liver. In comparison, 60% of the control cases had no liver pathology (normal liver), while 40% of the control cases had mild congestion or mild liver steatosis. None of the control subjects had liver cirrhosis.
Immunohistochemistry
IHC was performed on FFPE brain slides using a procedure modified from rat brain (Cook et al., 2014a) to detect cellular 3a,5a-THP levels. Slides were deparaffinized with xylene, rehydrated with gradually decreasing EtOH concentrations, and rinsed in phosphate-buffered saline (PBS) at pH 7.4. After rinsing, tissues were incubated in 0.6% H 2 O 2 to block endogenous peroxidase activity. Antigen retrieval was performed using 109 Citra Plus buffer (BioGenex, Fremont, CA) at pH 6.0 at 100°C for 30 minutes. This was followed by rinsing in PBS. Slides were then blocked for 1 hour with 10% rabbit serum (Vector Laboratories, Burlingame, CA) and incubated in the sheep affinity-purified anti-3a,5a-THP primary antibody (purchased from Dr. R.H. Purdy) in 1:2,500 dilution for 48 hours at 4°C. Next, sections were rinsed in PBS and followed by incubation in a rabbit anti-sheep biotinylated secondary antibody (Vector Laboratories) for 60 minutes. Avidin-biotin amplification was performed with Vectastain Elite ABC Kit (Vector Laboratories), and immunoreactivity was visualized with nickelenhanced 3,3 0 -diaminobenzidine (Sigma-Aldrich, St. Louis, MO) based on manufacturers' recommended protocol. Tissue was then dehydrated with gradually increasing EtOH concentrations and cleaned with xylene. Sections were coverslipped with Cytoseal XYL (Richard-Allen Scientific, Kalamazoo, MI) mounting media and sealed.
Anatomical Delineation
The term "VTA" has been used to refer to a collective name for parabranchial pigmented nucleus (PBP), paranigral nucleus (PN), parapeduncular nucleus (PaP), interfascicular nucleus (IF), rostral linear nucleus of the raphe (RLi), and caudal linear nucleus of the raphe (CLi) (Halliday, 2012; Halliday and Tork, 1986) . VTA is also described as a nucleus, which is found at the ventromedial aspect of the red nucleus and is situated medial to the PBP in the transverse plane (Halliday, 2012; McRitchie et al., 1996; Reyes et al., 2012) . We adopted this definition of the VTA nucleus term for this study (see Fig. 1 ).
The ventromedial aspect of the substantia nigra, known as the SNM, is located ventrolateral to the red nucleus and is found next to the VTA in the rostrocaudal transverse sections (Halliday, 2012; McRitchie et al., 1996) . VTA and SNM were sectioned in the transverse plane and examined simultaneously in the midbrain. Human amygdala slides were sectioned and examined in the coronal plane. Atlases of the human brain were used to identify anatomical boundaries and denomination of the subregions of the amygdaloid complex (Mai et al., 2008) .
IHC Analyses
Brain region immunoreactivity was visualized with an Olympus CX51 light microscope (Olympus America, Center Valley, PA); images were captured with a digital camera (Regita model; QImaging, Burnaby, BC, Canada) and analyzed using Bioquant (Nashville, TN) image analysis to obtain linear integrated optical density. The microscope, camera, and software were background-corrected to eliminate nonspecific labeling and normalized to preset light levels to ensure fidelity of the data acquisition. Immunoreactivity was quantified by pixel density/mm 2 from a circumscribed field, There was a 23.2 AE 9% increase in 3a,5a-THP immunoreactivity of AUD patients compared with controls (*p = 0.014) in the VTA. Figure (E) shows the comparison based on the liver pathology as AUD with cirrhosis, AUD with no cirrhosis, and controls in the VTA. There was 24.5 AE 10% increase in 3a,5a-THP immunostaining from AUD subjects with cirrhosis compared with controls (*p < 0.05). Figure ( F) shows the comparison between controls and AUD patients independently for each sex. Male AUD patients had 31.0 AE 11% higher 3a,5a-THP levels than male controls in the VTA (*p < 0.01) after the data were normalized to % of control values by sex. Figure ( G) shows the evaluation of the sex-related differences by comparing actual pixel density levels of 3a,5a-THP between males and females in the VTA. There was no difference in 3a,5a-THP immunostaining between male and female subjects (p > 0.05) in the VTA. ANOVA indicated no significant interaction between the effects of AUD and sex on 3a,5a-THP immunoreactivity (p = 0.73), and the main effect analysis showed that AUD produced an increase in 3a,5a-THP immunoreactivity (p = 0.032) in the VTA.
delineated as a brain region, divided by the area of the region in square millimeters. Additionally, positive cell count measurements were calculated from a defined region, divided by the area of the region in square millimeters (cell count/mm 2 ). Cell count analysis yielded similar results to pixel density/mm 2 analysis, suggesting that changes in the number of positive cells are a major component of pixel density analysis (data not shown). However, cell count data can be inaccurate when cells overlap in the field of analysis, usually leading to underestimation of the number of cells. Therefore, the results were only reported as pixel density/mm 2 to maximize accuracy and avoid duplication of the data. Data from 4 sequential sections per subject from a single hemisphere were used to average a single value per region. Three comparable regions in lateral amygdala, 2 comparable regions in basolateral amygdala, and 1 comparable region in VTA and SNM were analyzed under 49 magnification to average a single value per subject. The experimenter was blind to the condition of each subject when analyses were conducted.
Double Immunofluorescent Labeling of 3a,5a-THP with NeuN and TH
Double immunofluorescent labeling and confocal microscopy was performed on FFPE brain slides to detect cell types that exhibit 3a,5a-THP-positive immunostaining. After deparaffinization and rehydration, antigen retrieval was performed using 109 Citra Plus buffer at pH 6.0 at 100°C for 15 minutes. Slides were then rinsed in PBS and blocked for 1 hour with 10% donkey serum (Jackson Immunoresearch Labs Inc., West Grove, PA) and incubated in primary antibody for cell-type-specific markers: TH (1:1,000; ImmunoStar, Hudson, WI) or NeuN (1:1,000, (D4G40) XP; Cell Signaling Technologies, Danvers, MA) for 24 hours at 4°C. Next, slides were rinsed, blocked, and incubated with anti-3a,5a-THP primary antibody for 48 hours at 4°C. Then, sections were rinsed and incubated with secondary antibody (Alexa Fluor 488 for 3a,5a-THP visualization and Alexa Fluor 594 for cell-type-specific markers; Life Technologies, Carlsbad, CA). Immunofluorescence was visualized using a Leica SP2 laser scanning confocal microscope and computer software (Leica Microsystems Corp., Buffalo Grove, IL).
3a,5a-THP Antibody
The anti-3a,5a-THP antibody used for these studies was previously described (Cook et al., 2014a,b) . We observed cross-reactivity with 3a-hydroxy-4-pregnen-20-one (3a-HP; 41 AE 0.14%), (3a,5b)-3-hydroxy-pregnan-20-one (3a,5b-THP; 22 AE 0.43%), progesterone (14 AE 1.95%), 3a,5a-THDOC (11 AE 0.29%), and pregnenolone (9 AE 1.61%). In this study, we tested for cross-reactivity with the GABAergic metabolites of testosterone and DHEA by radioimmunoassay (RIA). Standards of 3a,5a-THP, 3a,5a-androstanediol, 3a,5b-androstanediol, 3a,5a-androsterone, and 3a,5b-androsterone were diluted in 95% EtOH at an initial concentration of 100 lg/ml. RIAs were repeated twice for each compound, following previously described methods (Cook et al., 2014a; Janis et al., 1998) . Briefly, 5 ll of each concentration of the steroids (14 concentrations, 40 -0.0049 ng/ml) was mixed with 10,000 counts per minute of [ H]3a,5a-THP was measured in a scintillation counter. The resulting curves were analyzed using a one-site competition model (Prism; GraphPad Software, La Jolla, CA) for EC 50 values. We observed minimal cross-reactivity with 3a,5a-androstanediol (1.13%), 3a,5b-androstanediol (1.3E-06%), 3a,5a-androsterone (0.85%), and 3a,5b-androsterone (0.66%).
Statistical Analysis
Raw pixel densities (average pixels/mm 2 ) were analyzed in amygdala sections and used for direct comparison. Due to large sample sizes of human midbrain sections (VTA and SNM), immunostaining was performed in sequential assays. Data from each assay were transformed to percent of control (individual mean/[control group mean] 9 100) values and compared statistically between groups. Student's t-tests (Prism; GraphPad software) were used to compare 3a,5a-THP levels from control subjects and AUD patients. Pearson's correlation was used to determine the association between lifetime total alcohol drinking (kg) and mean alcohol consumption per day with 3a,5a-THP immunoreactivity. Analysis of variance (ANOVA) was used to determine the effects of sex, liver status, and smoking status on 3a,5a-THP immunoreactivity. Pearson's correlation test and linear regression analysis were performed to determine the effect of age, PMI, and the length of time in fixation (TIF) with 3a,5a-THP immunoreactivity to detect potential confounding factors. All values were reported as mean AE SEM, and significance was defined at p ≤ 0.05. A single investigator conducted all IHC and statistical analyses.
RESULTS
Human Midbrain Samples
ANOVAs indicated no significant differences in age, F(1, 63) = 0.28, p = 0.98, PMI, F(1, 63) = 1.58, p = 0.31, or TIF, F(1, 63) = 0.52, p = 0.94, between controls and AUD patients in the VTA and SNM regions. There were no significant correlations between 3a,5a-THP immunoreactivity and age, PMI, or TIF of subjects in the VTA and SNM regions (Pearson's test, p > 0.05). It is notable that the average 3a,5a-THP immunoreactivity was 5.8 times higher in the SNM region than the VTA region (p < 0.0001).
3a,5a-THP Levels in Human VTA of AUD Patients Differed from Control Subjects Cellular 3a,5a-THP levels between AUD patients and control subjects were examined in the VTA. There was a 23.2 AE 9% increase in 3a,5a-THP immunoreactivity of AUD patients compared with controls, Student's t-test, t(63) = 2.517, p = 0.014, Fig. 1D , in the VTA. However, correlations between 3a,5a-THP immunoreactivity and total lifetime alcohol drinking (kg), r = À0.06, n = 38, p = 0.74, mean daily alcohol consumption (gram), r = À0.10, n = 36, p = 0.55, or total drinking years, r = 0.17, n = 38, p = 0.29, were not significant among AUD patients in the VTA by Pearson's tests.
Next, the effects of AUD were evaluated independently in each sex, such that male or female AUD patients were directly compared to their respective same sex controls, after the data were normalized to % control values. Male AUD patients had 31.0 AE 11% higher 3a,5a-THP levels than male controls in the VTA, Student's t-test, t(33) = 2.87, p < 0.01, Fig. 1F , but similar differences between female controls and AUD patients (21.8 AE 13%) did not reach significance (p > 0.05) in the VTA. To examine the possibility of sex differences, male and female subjects were reexamined in the same IHC assay, comparing actual pixel density levels of 3a,5a-THP and the related data were transformed as % of male controls (Fig. 1G) . In this experiment, there was no difference in 3a,5a-THP immunoreactivity between male and female subjects (p > 0.05). Two-way ANOVA with sex and AUD as factors indicated no interaction between the effects of AUD and sex on 3a,5a-THP immunoreactivity, F(1, 56) = 0.12, p = 0.73. The main effect analysis showed that AUD produced an increase in 3a,5a-THP immunoreactivity, F(1, 56) = 4.85, p = 0.032, while sex had no significant effect on 3a,5a-THP immunoreactivity (p = 0.13) in the VTA.
Sex-Specific Effect of AUD on 3a,5a-THP Immunoreactivity in SNM No significant difference in 3a,5a-THP immunoreactivity of AUD patients compared with controls was found in the SNM, Student's t-test, t(61) = 1.506, p = 0.14, Fig. 2D . Among AUD patients, correlations between 3a,5a-THP immunoreactivity and total lifetime alcohol drinking (kg), r = 0.09, n = 36, p = 0.64, mean daily alcohol consumption (gram), r = 0.17, n = 36, p = 0.32, or total drinking years, r = 0.05, n = 36, p = 0.77, were not significant in the SNM by Pearson's tests.
Sex-specific effects of AUD were examined as described above. First, the effects of AUD were evaluated independently in each sex. Male AUD patients had 29.6 AE 10% higher 3a,5a-THP levels than male controls in the SNM, Student's t-test, t(34) = 2.967, p < 0.01, Fig. 2E , while there was no significant difference between female AUD patients and female controls (p > 0.05), despite the observation that female AUD patients averaged 16.7 AE 9% lower 3a,5a-THP levels than female controls in the SNM. We also compared actual pixel density levels of 3a,5a-THP between males and females in a separate IHC experiment (Fig. 2G ). Female control subjects had 51.1 AE 18% higher 3a,5a-THP immunoreactivity than male controls in the SNM (p < 0.05). There was a statistically significant interaction between the effects of AUD and sex on 3a,5a-THP immunoreactivity, F(1, 55) = 7.04, p = 0.01, and the main effect analysis showed that sex had a significant effect on 3a,5a-THP immunoreactivity, F(1, 55) = 4.48, p = 0.038. We conclude 3a,5a-THP levels increased only in the male AUD patients compared with male controls and sex is an influencing factor on 3a,5a-THP levels in the SNM.
Potential confounding factors related to the 51.1 AE 18% increase in the female controls compared with male controls in the SNM were further explored. However, we found no significant difference in age, PMI, TIF, brain pH, mean daily alcohol consumption (gram), lifetime alcohol drinking (kg), total drinking years, and pack-years smoking history between female controls versus male controls (p > 0.05).
The Effect of Comorbidity with Liver Cirrhosis on 3a, 5a-THP Immunoreactivity in AUD
The subjects were compared based on the liver pathology as AUD with cirrhosis (n = 21), AUD with no cirrhosis (n = 17), and controls (n = 27) (Fig. 1F) by ANOVAs and post hoc analyses in the VTA. There was 24.5 AE 10% increase in 3a,5a-THP immunostaining for AUD subjects with cirrhosis compared with controls, F(2, 62) = 3.15, p < 0.05. The difference between AUD subjects with no cirrhosis and controls was not significant despite the observation that noncirrhotic AUD patients had 21.6 AE 11% higher 3a,5a-THP levels in the VTA (p > 0.05). There was no difference between 3a,5a-THP immunoreactivity of cirrhotic AUD patients and noncirrhotic AUD patients (p > 0.05) in the VTA. Thus, 3a,5a-THP levels in the VTA of the noncirrhotic and cirrhotic AUD patients were likely affected similarly.
As the effects of AUD on 3a,5a-THP immunoreactivity in SNM were only observed in the male subjects, the role of liver pathology was examined in 3 groups of male subjects: AUD with cirrhosis (n = 13), AUD with no cirrhosis (n = 14), and controls (n = 10) (Fig. 2F ). There was a 31.2 AE 9% increase in 3a,5a-THP immunoreactivity of male noncirrhotic AUD patients compared with the male controls, F(2, 34) = 4.76, p = 0.02. The difference between male AUD with cirrhosis and male controls was not significant despite the observation that male cirrhotic AUD patients had 21.8 AE 10% higher 3a,5a-THP levels in the SNM. There was no difference between 3a,5a-THP immunoreactivity of cirrhotic AUD patients and noncirrhotic AUD patients (p > 0.05) in the SNM. Thus, 3a,5a-THP levels in the SNM of the noncirrhotic and cirrhotic AUD patients were likely affected similarly.
We examined the role of smoking history in all subjects, as 66% of the controls and 75% of the AUD patients were reported as smokers. Average cigarette smoking was 33.3 AE 3 pack-years in all cases with no significant difference between controls and AUD patients (p = 0.35). There was also no significant correlation between pack-years smoking history and 3a,5a-THP immunoreactivity in either VTA or SNM regions (Pearson's test, p > 0.05).
3a,5a-THP Colocalizes with TH and NeuN in the VTA and SNM
To identify cell types in which 3a,5a-THP is localized in the VTA and SNM, we conducted double immunofluorescent labeling of 3a,5a-THP with NeuN and TH in human control subjects not included in the experiments above. We found that 3a,5a-THP shows a very high rate of colocalization with NeuN in the VTA and SNM (Fig. 3A,C) . This finding suggests that 3a,5a-THP is primarily localized in neurons in the VTA and SNM. We also observed that 3a,5a-THP was localized in TH-positive neurons to a large extent in the VTA and SNM (Fig. 3B,D) , suggesting that 3a,5a-THP is largely, but not exclusively, found in the dopaminergic neurons of the VTA and SNM.
TIF and Age Were Negatively Related to 3a,5a-THP Immunoreactivity in Human Amygdala Regions
ANOVAs indicated no significant differences in PMI, F(1, 34) = 0.017, p = 0.99, or age, F(1, 34) = 0.004, p = 0.99, or TIF, F(1, 34) = 0.65, p = 0.88, between controls and AUD patients in the lateral amygdala and basolateral amygdala. Pearson's test was used to assess correlations between 3a,5a-THP immunoreactivity and PMI (days), age (year), or TIF (days) in the lateral amygdala and basolateral amygdala. Figure (D) shows the comparison between controls and AUD patients. No significant difference in 3a,5a-THP immunoreactivity of AUD patients compared with controls was found in the SNM (p = 0.14). Figure (E) shows the comparison between controls and alcoholic subjects independently for each sex after the data were normalized to % of control values. Male AUD patients had 29.6 AE 10% higher 3a,5a-THP levels than male controls in the SNM (*p < 0.01). Figure (G) shows the evaluation of the sex-related differences by comparing actual pixel density levels of 3a,5a-THP between males and females in the SNM. Female control subjects had 51.1 AE 18% higher 3a,5a-THP immunoreactivity than male controls in the SNM (*p < 0.05). There was a statistically significant interaction between the effects of AUD and sex on 3a,5a-THP immunoreactivity (*p = 0.01), and the main effect analysis showed that sex had a significant effect on 3a,5a-THP immunoreactivity (p = 0.038). Figure (F) shows the comparison based on the liver pathology in the male subjects as AUD with cirrhosis, AUD with no cirrhosis, and controls in the SNM. There was a 31.2 AE 9% increase in 3a,5a-THP immunoreactivity of male noncirrhotic AUD patients compared with the male controls (*p = 0.02).
There was no correlation between 3a,5a-THP immunoreactivity and PMI in lateral or basolateral amygdala (p > 0.05). However, 3a,5a-THP levels were negatively related to the age of subjects in lateral amygdala (r = À0.37, p = 0.025, n = 36) and basolateral amygdala (r = À0.49, p = 0.0025, n = 36) (Fig. 4D,E) . 3a,5a-THP levels were also negatively related to the time in fixation of subjects in lateral amygdala (r = À0.41, p = 0.013, n = 36) and basolateral amygdala (r = À0.36, p = 0.032, n = 36) (Fig. 4F,G) . These factors confound the analysis of potential differences between controls and AUD patients. Nonetheless, we analyzed the lateral and basolateral amygdala regions to compare cellular 3a,5a-THP immunoreactivity between controls and AUD patients. There was no significant difference in 3a,5a-THP immunoreactivity between controls and AUD in the lateral amygdala, t(31) = 0.23, p = 0.82, Fig. 4H , and basolateral amygdala, t(31) = 0.22, p = 0.83, Fig. 4I .
DISCUSSION
The present set of experiments show that cellular 3a,5a-THP levels are 23.2 AE 9% higher in the VTA of human AUD patients compared with the age-matched controls. The difference in 3a,5a-THP levels in the VTA of AUD patients was driven by males. There was not a significant difference among female subjects, although the absolute difference was similar to male subjects. The lack of effect in females may be due to higher variability in 3a,5a-THP levels of female control subjects or the smaller sample size. Unfortunately, additional samples were not available for analysis. Likewise, 3a,5a-THP levels were significantly higher in the SNM of male AUD patients compared with the male controls, while there was no difference among female AUD patients compared with female controls.
Dual label confocal microscopy revealed that cellular 3a,5a-THP expression was primarily localized in TH-positive dopaminergic neurons in the VTA and SNM. This finding is consistent with our previous observation in rat brain (Cook et al., 2014b) . In general, increases in cellular 3a,5a-THP levels are associated with an enhancement in GABAergic tone, resulting in a reduction in the neuronal excitability (Akk et al., 2005; Sanna et al., 2004) . VTA dopaminergic activity increases after acute EtOH administration that is associated with the rewarding effect of EtOH and increased dopamine release within nucleus accumbens. Furthermore, withdrawal from chronic EtOH exposure reverses this effect and leads to a decrease in the activity of VTA dopaminergic neurons (Morikawa and Morrisett, 2010 ) that could be related to an increase in 3a,5a-THP levels in VTA dopamine neurons. It is well known that the last exposure time to Figure (D) and (E) indicates that 3a,5a-THP levels were negatively related to the age of subjects in lateral amygdala (Pearson's r value = À0.37, p = 0.025, n = 36) and basolateral amygdala (Pearson's r value = À0.49, p = 0.0025, n = 36). Figures (F) and (G) show that 3a,5a-THP levels were negatively related to the time in fixation of samples in lateral amygdala (Pearson's r value = À0.41, p = 0.013, n = 36) and basolateral amygdala (Pearson's r value = À0.36, p = 0.032, n = 36).
EtOH is an important determinant of the activity of VTA dopaminergic neurons. Unfortunately, no information was available related to the interval between the last exposure to alcohol and the death of the subjects. Thus, we are unable to report the alcohol status immediately before death. However, as the most common cause of death was chronic cardiorespiratory system failure, not accident or suicide, variations in drinking before death were likely, due to hospitalizations or disease-related impairments. Nonetheless, the increase in 3a,5a-THP levels may contribute to adaptive responses in the dopaminergic VTA neurons after chronic EtOH exposure. However, we cannot eliminate the probability that an increase in local 3a,5a-THP levels also affects the GABAergic and glutamatergic neurons in the VTA. While little is known about the VTA microcircuitry connections and subregions in human brain, further experimentation will be needed to understand how local 3a,5a-THP alterations in the VTA affect human mesolimbic activity and drinking behavior.
These results differ from studies in animal models of AUD. We have previously shown a decrease in 3a,5a-THP levels in the VTA of C57BL/6J mice after chronic intermittent EtOH exposure and withdrawal (Maldonado-Devincci et al., 2014) . In that study, we examined coronal sections of VTA at the level of bregma À3.08, while the human study examined VTA in the transverse plane at the level of the red nucleus. Therefore, we cannot rule out the possibility that differences in the VTA subregions investigated contribute to the different results in the 2 studies. Other studies reported a similar increase in whole brain 3a,5a-THP levels after voluntary EtOH consumption for 17 days in C57BL/6J mice (Finn et al., 2004) , decreases in cortical and hippocampal 3a,5a-THP concentrations following chronic EtOH exposure in rats (Cagetti et al., 2004; Janis et al., 1998) , and decreases in amygdala subregions of nonhuman primates after 1 year of EtOH consumption (Beattie et al., 2015) . Possible explanations for the discrepancy between human AUD patients and rodent models of chronic alcohol exposure include influences such as the age of the subjects (humans: age 57; rodents: young adults), duration of alcohol exposure (humans: 30 years; rodents: 2 to 6 weeks), and co-occurring liver disease in humans that is quite rare in rodent models of chronic alcohol exposure (Tsukamoto et al., 1995) . Furthermore, studies in rat models used RIA (Janis et al., 1998) or gas chromatography-mass spectroscopy (Cagetti et al., 2004) to measure 3a,5a-THP levels, while levels in human VTA and SNM were determined by IHC. Another notable difference in this study is the presence of EtOH exposure in human control subjects. Social drinkers who consumed 1 to 2 drinks per day were analyzed as control subjects in this study. On the other hand, alcohol na€ ıve animals were used as the control group in all rodent studies. Therefore, differences between animal models and human studies should be taken into consideration.
Increases in 3a,5a-THP levels in the VTA and partially in the SNM (only among male subjects) are concordant with a recent postmortem brain study examining steroid levels in human AUD patients. In the study, pregnenolone (a precursor to 3a,5a-THP) and DHEA (a precursor of the GABAergic neuroactive steroid, androsterone) levels were higher in most limbic brain regions in AUD patients, compared with nonalcoholic controls (Karkkainen et al., 2016) . Together, these findings may indicate a global increase in neurosteroid content in the brains of human AUD patients. Further studies are needed to test this hypothesis.
Potential cross-reactivity of anti-3a,5a-THP antibody with other neurosteroids should be taken into consideration. We have previously observed a 9 AE 1.6% cross-reactivity of anti-3a,5a-THP antibody with pregnenolone (Cook et al., 2014a) , which may contribute to the similar outcomes with the recent postmortem human study (Karkkainen et al., 2016) . Cross-reactivities between anti-3a,5a-THP antibody and other neurosteroids such as 3a-HP or 3a,5b-THP have been also discussed in the previous work (Cook et al., 2014a) . Additionally in this study, we detected negligible cross-reactivity between anti-3a,5a-THP antibody with 3a-reduced androstanes (see Materials and Methods), suggesting that the interactions with anti-3a,5a-THP and 3a-reduced androstanes are minimal.
The difference in the ages of human subjects versus rodent studies deserves further consideration. We examined human AUD patients at an average age of 57, which would correspond to an 18+-month-old rat (Sengupta, 2013) . In comparison, studies investigating the effect of chronic EtOH exposure on brain 3a,5a-THP levels have primarily been conducted in 2-to 4-month-old young adult rodents (Cagetti et al., 2004; Janis et al., 1998; Maldonado-Devincci et al., 2014) leaving gaps in our knowledge in the effect of alcohol on the neurosteroid levels in rodents versus humans. Aged humans show differential GABA A receptor subunit expression (Kanaumi et al., 2006) , have higher physiological sensitivity to alcohol (Menninger, 2002) , and are more susceptible to the deficits associated with chronic AUD (Pfefferbaum et al., 1992) . Further, aged animals show greater EtOHinduced memory impairment and exhibit fewer withdrawal symptoms compared with adult animals (Novier et al., 2016) , suggesting that aged adult individuals have unique responses to chronic EtOH exposure. In this study, we also show that 3a,5a-THP concentrations are negatively correlated with age in amygdala regions, but not in the VTA and SNM regions. These finding may suggest that the 3a,5a-THP content in various brain areas are affected by the aging process differently.
Patients with a diagnosis for psychiatric, neurologic, and neurodegenerative conditions were excluded from the study to eliminate confounding factors. However, AUD causes secondary medical conditions, including alcoholic liver disease. Cirrhosis is the final phase of alcoholic liver disease, characterized by irreversible hepatic tissue transformation. In our study, more than half of the AUD patients were complicated with liver cirrhosis, while the remaining AUD patients had milder and reversible manifestations of liver disease such as congestion or steatosis. Only 5% of the AUD patients showed no signs of liver disease. In our study, we found no significant difference in 3a,5a-THP brain levels of noncirrhotic AUD patients compared with cirrhotic alcoholics, suggesting that AUD is the main factor in the observed increase in AUD patients. However, others have reported that in the majority of male individuals with alcoholic fatty liver change and alcoholic cirrhosis, 3a,5a-THP precursor progesterone plasma levels were above the upper limit of normal plasma progesterone concentration (Farthing et al., 1982) . Moreover, increase in plasma 3a,5a-THP concentrations has been also shown in nonalcoholic liver injuries (Ahboucha et al., 2008) . Besides, 3a,5a-THP is known to readily cross the blood-brain barrier (Zhu et al., 2001 ) and 3a,5a-THP precursors are metabolized in the liver (Stanczyk, 2003) . 3a,5a-THP levels were also significantly higher in the brain extracts from hepatic encephalopathy patients who died in hepatic coma (Ahboucha et al., 2006 ), but no difference was found between patients with uncomplicated liver disease and controls. Therefore, we conclude that 3a,5a-THP elevations in VTA are not substantially moderated by liver disease.
In the SNM, female control subjects averaged 51 AE 18% higher brain 3a,5a-THP levels than male control subjects, but this effect was not observed in the VTA. In this study, we also compared VTA and SNM 3a,5a-THP levels between premenopausal women (<48 years) versus postmenopausal women (>55 years) by grouping them according to adjusted median age of natural menopause (51.7 years) in the Australian population (Do et al., 1998) . However, comparisons of these 2 age groups were not significantly different in any brain region studied (data not shown). Other human studies show that average brain progesterone and 3a,5a-THP concentrations were significantly higher in the fertile women in the luteal phase of the menstrual cycle compared with their postmenopausal controls (Bixo et al., 1997) , suggesting that females have higher basal 3a,5a-THP levels in the brain. Together, these findings may suggest that the basal 3a,5a-THP content in female brain is likely higher than male brain, but different brain areas may show greater sensitivity to sexrelated effects.
Studies in amygdala sections of human AUD patients were confounded by the effects of fixation time in formalin. It is well known that IHC is greatly influenced by the fixation time in formalin (Grillo et al., 2015) . Accordingly, we found that 3a,5a-THP levels in the lateral amygdala and basolateral amygdala are negatively correlated with the fixation time in formalin. Average length of fixation time for human amygdala samples was more than 6 years, producing a challenge to measure 3a,5a-THP levels in amygdala regions. We also observed a negative correlation between age and 3a,5a-THP levels that may also confound the analysis of potential differences between control and AUD patients. On the other hand, VTA and SNM samples were fixed in formalin for less than a month on average, and there was no correlation between 3a,5a-THP levels and fixation time in the VTA or SNM. Therefore, antigenic epitopes in the VTA and SNM regions may be relatively preserved from any masking effect of formalin.
The observation that 3a,5a-THP levels were decreased with aging in amygdala, but not VTA or SNM, of humans subjects suggests regional variation in regulation of 3a,5a-THP synthesis or degradation. Animal studies examining the effect of aging on 3a,5a-THP brain levels have yielded inconsistent results. Brain 3a,5a-THP content showed a significant progressive decrease with age in Wistar rats (Bernardi et al., 1998) but showed no difference between 2-month-old and 18-month-old Sprague Dawley rats . A similar decline has been observed in several rat brain regions that could be linked to sleep cycle alterations and cognitive impairment in aged rat populations (George et al., 2010) . Taken together, 3a,5a-THP levels may show a regionspecific decrease in the brain with age that could contribute to physiological aging or age-related pathological conditions. Thus, future studies are required to expand our understanding of age-related differences.
The study had several limitations. First, relative values of immunoreactivity were determined via measuring the pixel density within a prescribed field over preestablished baseline levels. Therefore, values are relative and expressed as percent control or average pixel density, making it impossible to compare absolute 3a,5a-THP levels in the brain regions. Second, other GABAergic neuroactive steroid levels should be measured to understand the complete neurosteroid pattern in postmortem human brain regions. Moreover, highly relevant brain regions including nucleus accumbens, hippocampus, prefrontal cortex, and anterior cingulate cortex should be investigated to compare data with rodent studies that examined more regions.
Alterations in 3a,5a-THP levels may contribute to adaptive responses in VTA neurons or the elevation of 3a,5a-THP levels may represent a biomarker of alcohol abuse. The differences between animal models and human studies should be considered to determine the physiological significance of elevated 3a,5a-THP levels in humans. In conclusion, cellular 3a,5a-THP levels in the VTA are increased in human AUD patients that are likely independent of sex and liver disease. Further studies are needed to determine the physiological significance of elevated 3a,5a-THP levels in humans.
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